Bromodomain and Extra-Terminal (BET) Domain Protein Inhibitors for Solid Tumor Cancers
The bromodomain and extraterminal (BET) domain protein family is involved in the process of transcription of genetic information. The BET protein family includes BRD2, BRD3, BRD4, and bromodomain testis-specific protein. BET protein alterations are associated with some solid tumor cancers, including...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Innovative Healthcare Institute
2020-02-01
|
| Series: | Journal of Immunotherapy and Precision Oncology |
| Subjects: | |
| Online Access: | https://jipo.org/doi/pdf/10.4103/JIPO.JIPO_2_20 |
| Summary: | The bromodomain and extraterminal (BET) domain protein family is involved in the process of transcription of genetic information. The BET protein family includes BRD2, BRD3, BRD4, and bromodomain testis-specific protein. BET protein alterations are associated with some solid tumor cancers, including nuclear protein in testis midline carcinoma. BET protein has a role in carcinogenesis and in the regulation of the cell cycle. A number of BET inhibitors have entered clinical trials. This review discusses the results of BET inhibitor clinical trials in solid tumor cancers. |
|---|---|
| ISSN: | 2666-2345 2590-017X |